EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access

Biomarkers to predict disease progression and therapeutic response in isolated methylmalonic acidemia

Irini Manoli iD, Abigael Gebremariam, Samantha McCoy, Alexandra R Pass, Jack Gagné, Camryn Hall, Susan Ferry, Carol Van Ryzin, Jennifer L Sloan iD, Elisa Sacchetti iD, Giulio Catesini iD, Cristiano Rizzo iD und 4 weitere

Journal of Inherited Metabolic Disease · 2023

DOI: 10.1002/jimd.12636 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Inherited Metabolic Disease, 2023. Verfasst von Irini Manoli und 15 weiteren Autor:innen. Beteiligte Einrichtung: Metabolic Medicine Branch, National Human Genome Research Institute, National Institutes of Health (NIH), Bethesda, Maryland, USA. Hauptthemen laut MEDLINE: Amino Acid Metabolism, Inborn Errors. Die Arbeit wurde bisher 26-mal zitiert (Crossref) und nennt 132 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Intramural NIH HHS, National Human Genome Research Institute, Ministero della Salute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Methylmalonic Acidemia (MMA) is a heterogenous group of inborn errors of metabolism caused by a defect in the methylmalonyl‐CoA mutase (MMUT) enzyme or the synthesis and transport of its cofactor, 5′‐deoxy‐adenosylcobalamin. It is characterized by life‐threatening episodes of ketoacidosis, chronic kidney disease, and other multiorgan complications. Liver transplantation can improve patient stability and survival and thus provides clinical and biochemical benchmarks for the development of hepatocyte‐targeted genomic therapies. Data are presented from a US natural history protocol that evaluated subjects with different types of MMA including mut ‐type ( N = 91 ), cblB ‐type (15), and cblA‐ type MMA (17), as well as from an Italian cohort of mut ‐type ( N = 19) and cblB ‐type MMA ( N = 2) subjects, including data before and after organ transplantation in both cohorts. Canonical metabolic markers, such as serum methylmalonic acid and propionylcarnitine, are variable and affected by dietary intake and renal function. We have therefore explored the use of the 1‐ 13 C‐propionate oxidation breath test (POBT) to measure metabolic capacity and the changes in circulating proteins to assess mitochondrial dysfunction (fibroblast growth factor 21 [FGF21] and growth differentiation factor 15 [GDF15]) and kidney injury (lipocalin‐2 [LCN2]). Biomarker concentrations are higher in patients with the severe mut 0 ‐type and cblB ‐type MMA, correlate with a decreased POBT, and show a significant response postliver transplant. Additional circulating and imaging markers to assess disease burden are necessary to monitor disease progression. A combination of biomarkers reflecting disease severity and multisystem involvement will be needed to help stratify patients for clinical trials and assess the efficacy of new therapies for MMA.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Amino Acid Metabolism, Inborn ErrorsHumansMutationBiomarkersDisease ProgressionMethylmalonic AcidMethylmalonyl-CoA Mutase

Stichwörter der Autor:innen

FGF21GDF15biomarkerclinical trial endpointmethylmalonic acidemiapropionate oxidationstable isotope

Substanzen

BiomarkersMethylmalonic AcidMethylmalonyl-CoA Mutase

Autor:innen und Institutionen

  • Metabolic Medicine Branch, National Human Genome Research Institute, National Institutes of Health (NIH), Bethesda, Maryland, USA.
  • Division of Metabolic Diseases, Bambino Gesù Children's Hospital IRCCS, Rome, Italy.
  • Division of Hepato-Bilio-Pancreatic Surgery, Liver and Kidney Tranplantation, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy.
  • European Research Network TransplantChild, Rome, Italy.

ORCID-Profile: Irini Manoli, Jennifer L Sloan, Elisa Sacchetti, Giulio Catesini, Cristiano Rizzo, Diego Martinelli, Marco Spada, Carlo Dionisi-Vici, Charles P Venditti

Förderung

  • Intramural NIH HHS
  • National Human Genome Research Institute
  • Ministero della Salute

Zitieren

APA

Manoli, I., Gebremariam, A., McCoy, S., Pass, A. R., Gagné, J., Hall, C., Ferry, S., Van Ryzin, C., Sloan, J. L., Sacchetti, E., Catesini, G., Rizzo, C., Martinelli, D., Spada, M., Dionisi-Vici, C., & Venditti, C. P. (2023). Biomarkers to predict disease progression and therapeutic response in isolated methylmalonic acidemia. Journal of Inherited Metabolic Disease. https://doi.org/10.1002/jimd.12636

Vancouver

Manoli I, Gebremariam A, McCoy S, Pass AR, Gagné J, Hall C, et al. Biomarkers to predict disease progression and therapeutic response in isolated methylmalonic acidemia. Journal of Inherited Metabolic Disease. 2023. doi:10.1002/jimd.12636

BibTeX
@article{Manoli2023,
  author = {Manoli, Irini and Gebremariam, Abigael and McCoy, Samantha and Pass, Alexandra R and Gagné, Jack and Hall, Camryn and Ferry, Susan and Van Ryzin, Carol and Sloan, Jennifer L and Sacchetti, Elisa and Catesini, Giulio and Rizzo, Cristiano and Martinelli, Diego and Spada, Marco and Dionisi-Vici, Carlo and Venditti, Charles P},
  title = {Biomarkers to predict disease progression and therapeutic response in isolated methylmalonic acidemia},
  journal = {Journal of Inherited Metabolic Disease},
  year = {2023},
  doi = {10.1002/jimd.12636}
}
Kostenlos starten →